Joincare(SH:600380)2023-04-24 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 4.56 billion, a decrease of 2.11% year-on-year[4]. - Net profit attributable to shareholders was CNY 462.75 million, an increase of 0.48% compared to the same period last year[4]. - Revenue from chemical preparations was CNY 2.25 billion, down 16.09% year-on-year, while revenue from traditional Chinese medicine preparations increased by 100.68% to CNY 567 million[5]. - Total operating revenue for Q1 2023 was ¥4,559,049,786.82, a decrease of 2.12% compared to ¥4,657,343,538.89 in Q1 2022[16]. - Net profit for Q1 2023 was ¥878,518,035.31, an increase of 1.89% from ¥862,357,260.73 in Q1 2022[16]. - The company’s total comprehensive income for Q1 2023 was ¥794,846,461.55, compared to ¥755,509,486.13 in Q1 2022, showing overall growth[17]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 71.55% to CNY 248.08 million due to increased raw material procurement costs and reduced sales collections[4][10]. - The net cash flow from operating activities was CNY 248,084,750.71, significantly down by 71.5% from CNY 871,904,476.98 in the same period last year[18]. - The total cash inflow from operating activities was CNY 4,604,364,859.54, a decrease of 4.46% compared to CNY 4,819,770,651.03 in Q1 2022[18]. - The cash inflow from financing activities was CNY 1,249,525,870.74, down 40.8% from CNY 2,107,748,905.15 in Q1 2022[19]. - The net cash flow from financing activities was negative at CNY -118,644,351.81, contrasting with a positive flow of CNY 62,714,553.34 in the previous year[19]. - The total cash and cash equivalents at the end of Q1 2023 stood at CNY 14,188,620,865.54, an increase from CNY 12,541,970,131.84 at the end of Q1 2022[19]. Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 36.19 billion, reflecting a 1.30% increase from the end of the previous year[4]. - The company's cash and cash equivalents stood at RMB 14.46 billion, slightly down from RMB 14.81 billion at the end of 2022, indicating a decrease of about 2.36%[14]. - Accounts receivable increased to RMB 3.26 billion, up from RMB 3.10 billion, representing a growth of approximately 5.03%[14]. - Inventory levels rose to RMB 2.79 billion, compared to RMB 2.56 billion at the end of 2022, marking an increase of around 8.86%[14]. - The total liabilities decreased to RMB 20.54 billion from RMB 20.73 billion, a reduction of about 0.92%[14]. - The company reported a total liability of ¥13,845,357,862.33 as of Q1 2023, slightly up from ¥13,709,025,953.74 in Q1 2022[15]. Investments and Shareholder Equity - Investment income rose by 35.81% to CNY 39.63 million, attributed to received dividends during the reporting period[10]. - The long-term equity investments increased to RMB 1.43 billion, compared to RMB 1.42 billion at the end of 2022, showing a growth of about 0.48%[14]. - The equity attributable to shareholders of the parent company increased to ¥13,365,070,332.08 in Q1 2023 from ¥13,121,820,410.55 in Q1 2022[15]. - The company reported a total of 58,122,392 shares repurchased, accounting for approximately 3.01% of total shares[13]. - The number of GDRs outstanding was 1,378,023, representing 21.59% of the total issued GDRs[12]. Research and Development - Research and development expenses increased to ¥381,172,496.49 in Q1 2023, compared to ¥351,331,244.23 in Q1 2022, indicating a focus on innovation[16].